Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.…

Key PointsNon-GAAP EPS was $0.15, beating the non-GAAP estimate of $0.09 and turning positive on a GAAP basis from a…

Key PointsRevenue (GAAP) soared 164% year over year to $81.5 million, surpassing analyst estimates by $7.81 million (GAAP).Net loss per…

…

1 August 2025 Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…

U.S. stock index futures extended losses on Friday after a weaker-than-expected July jobs report elevated concerns about the health of…

Key PointsIonis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide…

Its that time again ... so, lets take a look at five pieces of content worth digging into deeper this…

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after…

Aradhana Sarin, AstraZeneca CFO, says the company is making a significant commitment to the U.S., explaining that the majority of…

On todays episode of Bloomberg Businessweek Daily with Tim Stenovec and Carol Massar, Pascal Soriot, Chief Executive Officer of AstraZeneca…

Morningstar‘s US growth index is dominated by the “ Magnificent Seven.” But internationally, the scale is far smaller. There…

From pharma giants to sausage rolls, it was a day of upbeat numbers and market milestones. AstraZeneca soared, Barclays delivered…

CNBCs Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the companys most recent quarter, investment in innovation in…

TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.…

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was…

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca nach Zahlen auf "Hold" mit einem Kursziel…

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines…

AstraZeneca beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand in the…

CAMBRIDGE (dpa-AFX) - Gute Geschäfte mit seinen Impfstoffen und Krebsmedikamenten haben den Pharmakonzern Astrazeneca im zweiten Quartal unerwartet viel…